PRESS RELEASE
Published on June 7, 2007
[Missing
Graphic Reference]
NEOGENOMICS,
INC
PRESS
RELEASE
Investor
Relations Contacts:
Steven
C.
JonesFrank N. Hawkins or Julie Marshall
Director
of Investor RelationsHawk and Associates, Inc.
(239)
325-2001(305)-451-1888
sjones@neogenomics.org info@hawkassociates.com
12701
Commonwealth Drive, Suite 9
Fort
Myers, FL 33913
FOR
IMMEDIATE RELEASE
NeoGenomics
Announces $4 Million of New Equity Financing and
$4
Million of New Credit Availability
Company
also Announces the Addition of Two New Board Members
and
Continued
Strong Momentum in New Customer Additions
Ft.
Myers,
Florida – June 7, 2007 – NeoGenomics,
Inc.
(NASD OTC BB: NGNM),
a
leader in the
rapidly evolving field of cancer genetics testing, announced
today that a group of investors has purchased $4 million of common stock from
NeoGenomics in a private transaction. The transaction was priced at
$1.50 per share and resulted in 2.67 million shares of new common stock being
issued by the Company. No warrants were issued as part of the
transaction. The Company used $1.7 million of the proceeds to pay off
all of its existing short-term indebtedness. After payment of fees
and expenses, the remaining approximately $2 million will be held in cash
reserve for general corporate purposes. Noble Financial Group acted
as the placement agent for this transaction.
NeoGenomics
also announced that it has entered into a term sheet for a $4 million Credit
Facility with Wachovia Bank. The Credit Facility will be comprised of
two parts; a $2 million working capital facility based on eligible accounts
receivable and a $2 million capital expenditures
facility. Pricing on the accounts receivable facility will be
LIBOR plus 3.02% and pricing on the capital expenditures portion will be at
LIBOR plus 2.76%. None of the Credit Facility will be drawn at close,
rather it will be held in reserve to facilitate the Company’s continued
expansion activities if needed. Definitive transaction documents are
expected to be executed by the Company and Wachovia Bank within 10
days.
In
other
news, the Company announced that its existing Board of Directors had been
re-elected by shareholders for another term and that Mr. William J. Robison
and
Dr. Marvin E. Jaffe had joined the Company’s Board of Directors. Mr.
Robison, who is retired, spent his entire 41 year career with Pfizer,
Inc. At Pfizer, he rose through the ranks of the sales organization
and became Senior Vice President of Pfizer Labs in 1986. In 1990, he
became General Manager of Pratt Pharmaceuticals, a then new division of the
U.S.
Pharmaceuticals Group, and in 1992 he became the President of the Consumer
Health Care Group. In 1996 he became a member of Pfizer’s Corporate
Management Committee and was promoted to the position of Executive Vice
President and head of Worldwide Corporate Employee Resources. Mr.
Robison retired from Pfizer in 2001 and currently serves as a consultant and
board member to various companies.
Dr.
Jaffe, who is also retired, spent his entire working career in the
Pharmaceutical Industry and has been responsible for the pre-clinical and
clinical development of new drugs and biologics in nearly every therapeutic
area. He began his career at Merck & Co and spent 18 years
with Merck, rising to the position of Senior Vice-President of Medical
Affairs. After leaving Merck, Dr. Jaffe became the founding President
of the R.W. Johnson Pharmaceutical Research Institute (PRI), a Johnson &
Johnson Company. PRI was established for the purpose of
providing globally integrated research and development support to several
companies within the J&J pharmaceutical sector including Ortho
Pharmaceutical, McNeil Pharmaceutical, Ortho Biotech and Cilag. Dr.
Jaffe retired from Johnson & Johnson in 1994 and currently serves as a
consultant and board member to various companies in the biopharmaceutical and
biotechnology industries.
Mr.
Robert Gasparini, the Company’s President and Chief Scientific Officer, stated,
“The achievements we are reporting today represent a turning point in the
evolution of NeoGenomics. I am delighted to report that our stock
offering was well received and significantly oversubscribed. Indeed,
we are truly honored that so many institutional investors have elected to become
shareholders in our Company. To have the confidence of the
institutional investment community at this stage of our development is perhaps
one of the greatest complements that we could receive. Absent any
major new strategic initiatives, we believe this equity raise and the new debt
facility will fully fund our business plan for the foreseeable
future.”
Mr.
Gasparini went on to say, “We are also incredibly honored to welcome our two new
Board Members. People with the business experience and savvy of Dr.
Jaffe and Mr. Robison have many options in their retirement, and we are most
pleased that they have accepted our invitation to join the NeoGenomics Board
of
Directors. Each of them brings a wealth of experience to our Board in
their related areas of expertise, and we believe they will be invaluable
resources in helping us execute on our strategy in the rapidly evolving field
of
cancer genetics.”
Mr.
Gasparini finished by saying, “I am also very pleased to announce that our sales
momentum is continuing at a strong pace. We are now up to 12 sales
representatives in total, and through the first two months of the second quarter
we have added 25 new customers. This is in addition to the 27 new
customers gained in Q1 that we reported just three weeks ago. This
level of sales productivity speaks volumes about the relevance and reception
of
our products in the marketplace. Our Tech-only NeoFISHTM product
continues
to be warmly received by the pathology community and we have recently added
some
very large customers. We are excited about our third and fourth
quarter outlook as a result of these new customers.”
Mr.
Steven Jones, the Company’s Acting Chief Financial Officer, added the following,
“Our equity transaction was priced at an approximately 10% discount to the
average market price during the pricing period, and we were able to conclude
this transaction without offering the traditional 25-50% warrant
coverage that is usually required in capital raises for OTC Bulletin Board
Companies. This is very strong pricing for a first institutional
raise and we believe it is a terrific acknowledgement by the institutional
investment community of our significant growth potential. In
addition, by paying off our existing 14.25% interest rate debt with equity,
we
will save approximately $330,000 per year of cash and non-cash interest expense
which we believe will result in approximately $0.01 per share of incremental
earnings per year on a moving forward basis. Also, to the extent we
need to borrow on our new Credit Facility, the implied interest rate is
currently approximately 8.0 – 8.25%, which is much more manageable than our
previous high coupon debt facility. We now have approximately $2
million of cash and $4 million of credit available to us to pursue growth
initiatives. This is substantially more dry powder than we have ever
had before.”
Mr.
Jones
went on to say, “I would also like to remind our investors that there is
typically a 3-4 month lag between the time that we land a new customer and
the
time that such customer gets to its targeted revenue potential with
NeoGenomics. This is due to the normal ramp up and break-in
period with all new customers. Given the strong growth in new
customer adds that began late in the first quarter and is continuing into the
second quarter, we have begun to aggressively ramp up our staff to handle the
coming expected volumes in Q3 and Q4.”
“I
also
need to report that we finally lost one of our two large reference lab accounts
earlier this quarter as they brought their FISH testing
in-house. This has been expected by us for some time now, we just
didn’t know when it would come. It is part of the ongoing evolution
of our customer mix more towards community-based pathologists and oncologists
that we first reported on in Q3 06. As a result of this, there will
be a significant near term impact on our sequential revenue growth in
Q2. We view this as more of a timing issue than anything else, and we
believe that any lost revenue in Q2 should be more than offset by the positive
revenue impacts of new customers ramping up in Q3 and Q4. However, at
this point, in time we are reducing our guidance for sequential revenue growth
from Q1 to Q2 to approximately 10-20%. In addition, as a result of
ramping up our staff and these near term revenue impacts, we now expect to
incur
a net loss in Q2 of approximately $0.01/share, before taking into consideration
any one-time charges associated with the early extinguishment of our
debt.”
Mr.
Jones
concluded by saying, “As a result of the Company’s new liquidity position from
the equity raise and the availability on the new Credit Facility, we do not
plan
to renew our Standby Equity Distribution Agreement (“SEDA”) with Cornell Capital
Partners when it expires this coming August. Although we did not use
the SEDA to take down much capital, we believe it gave us significant financing
flexibility as we executed on our business plan over the last two
years.”
About
NeoGenomics, Inc.
NeoGenomics,
Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in
cancer genetics diagnostic testing, the fastest growing segment of the
laboratory industry. The company’s testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
morphology studies, anatomic pathology and molecular genetic
testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists,
oncologists, urologists, hospitals and other reference laboratories throughout
the United States. For additional information about NeoGenomics,
visit http://www.neogenomics.org.
Interested
parties can also access additional investor relations material, including an
in-depth equity research report, from the American Microcap Institute at
http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at
http://www.hawkassociates.com. An investment profile about
NeoGenomics may be found at
http://www.hawkassociates.com/ngnmprofile.aspx.
Forward
Looking Statements
Except
for historical information, all of the statements, expectations and assumptions
contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in
the forward looking statements, Actual results could differ materially from
such
statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company’s ability to continue gaining new
customers, offer new types of tests, and otherwise implement its business plan.
As a result, this press release should be read in conjunction with the company's
periodic filings with the SEC.